Key Highlights:
- Jefferies upgrades Nektar Therapeutics (NKTR, Financial) to "Buy" due to favorable risk-reward dynamics.
- Anticipation builds for Phase 2b trial results of eczema treatment, rezpeg, by mid-2025.
- Analyst price predictions suggest significant potential upside for NKTR stock.
Nektar Therapeutics (NKTR) recently experienced a notable stock surge following an upgrade to a "Buy" by Jefferies. The investment firm points to an appealing risk-reward proposition, particularly as investors await the mid-2025 release of Phase 2b trial results for rezpeg, an innovative eczema treatment. The drug's novel mechanism and robust safety profile have generated positive market sentiment.
Wall Street Analysts Forecast
Current analysis from six experts reveals a one-year average target price for Nektar Therapeutics (NKTR, Financial) positioned at $4.75. Projections range from a low of $1.00 to a high of $7.00, suggesting an impressive potential upside of 707.82% from the present share value of $0.59. For more in-depth estimates, visit the Nektar Therapeutics (NKTR) Forecast page.
Nektar Therapeutics's (NKTR, Financial) average brokerage recommendation stands at 2.3, aligning with an "Outperform" status. This consensus is drawn from eight brokerage firms within a scale where 1 denotes a Strong Buy and 5 indicates a Sell.
GuruFocus Valuation Metrics
GuruFocus estimates project the GF Value for Nektar Therapeutics (NKTR, Financial) at $0.86 in the forthcoming year. This points to a projected upside of 46.26% from the current price of $0.588. The GF Value represents GuruFocus's approximation of fair trading value for the stock, calculated using historical price multiples, past growth metrics, and future business forecasts. Further details are accessible on the Nektar Therapeutics (NKTR) Summary page.
